When it comes to health startups, there are very few companies which are getting success in finding new ways to cure severe diseases. A Colorado-based startup named Partner Therapeutics started a year ago to find a cure to treat leukaemia. They began with a single leukine medicine which was approved in 1991, and many doctors nowadays don’t prescribe it anymore. Now the startup is trying to shift their focus on this medicine from a different perspective; also, they are testing whether Leukine can be used to cure Alzheimer’s. There are many large companies which have spent billions of dollars on finding a cure for Alzheimer‘s, but they failed to do that.
One of the critical parts of these researchers was that they were trying to find a treatment for removal of amyloid plaques, an accumulation of debris on the brain tissue, which is the first sign of Alzheimer. Now startups are trying to work on a new thesis to find a way a new way to solve the severe problem of Alzheimer. Researchers said that the large companies have so far spent billions of their funding on finding a cure, but they have got no success in it. Now small companies like Partner therapeutics can come and solve this problem. Large companies have made it clear that they are not going to take the initiative by themselves, but they are funding small companies for the same cause.
Big companies like Johnson & Johnson, Biogen, Eli Lilly and AstraZeneca have faced lots of failures, and now they are all shifting their focus. Drug companies are targeting Alzheimer diseases are going through failures, but more than 1,100 new drugs for cancer, 445 for other neurological disorders, and 200 for heart diseases have found by researchers. Now, this data gives us hope that even though health companies are failing to solve the problem of Alzheimer’s, they are finding new ways to cure other severe diseases.
Paul is an American-based writer covering Latest business trends. Paul cover Business and media for many news sites. He has been breaking news and writing features on these topics for major publications since 2012. Paul prefers writing about business news keeping science and technology into perspective.